Search

Search Constraints

You searched for: Author/Creator Agarwal, Shefali

Search Results

3. EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study. Issue 6 (June 2022)

4. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. Issue 2 (February 2017)

6. Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC. Issue 5 (18th January 2018)

7. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial. Issue 8 (August 2018)

8. Real‐world outcomes of patients with locally advanced or metastatic epithelioid sarcoma. Issue 8 (9th December 2020)

9. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Issue 11 (November 2020)

10. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. Issue 11 (November 2020)